Table 2.

Adverse Events Leading to Modifications in Treatment Plan in Selinexor Studies

	Treatment Holiday/Interruption	Dose Reduction	Treatment Termination
Vogl et al5	52% (n=41/79)	37% (n=29/79)	18% (n=14/79)
Bahlis et al3		50% (n=21/42)	19% (n=8/42)
Jakubowiak et al21	80% (n=17/21)	62% (n=13/21)	10% (n=2/21)
Chen et al2			31% (n=26/84)